CDSCO Panel Denies Pfizer Products India request for local CT waiver to market Elranatamab solution for injection
New Delhi: Noting that no new data, literature, or updates have been presented by the firm, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has rejected the drug major Pfizer Products India's proposal for waiver of local clinical trials for the grant of permission to import and market Elranatamab solution for injection.
Elranatamab is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma. In the US, it is approved for patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
After detailed deliberation, the committee reiterated the earlier SEC recommendation dated April 3, 2024, stating:
"The committee did not consider the firm’s request for waiver of local clinical trial for grant of permission to import and market Elranatamab solution for injection.”
Also Read:CDSCO declares 5 formulations as spurious: Details
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.